2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Dermatologic
2
Conditions
Mycosis Fungoides
3
Lymphoma, T-Cell, Cutaneous
3
Neoplasms
2
Lymphoproliferative Disorders
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lymphatic Diseases
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia-Lymphoma, Adult T-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Cyclophosphamide
32
Etoposide
18
romidepsin
17
fludarabine
17
Vincristine
17
Doxorubicin
16
Rituximab
14
Prednisone
14
Melphalan
14
Gemcitabine
13
Brentuximab Vedotin
13
Lenalidomide
12
Peripheral Blood Stem Cell Transplantation
11
Cytarabine
11
Whole-Body Irradiation
10
Biopsy
10
10-propargyl-10-deazaaminopterin
10
pembrolizumab
9
fludarabine phosphate
9
Specimen Handling
9
Busulfan
9
Mycophenolic Acid
8
Granulocyte Colony-Stimulating Factor
8
Depsipeptides
8
Carmustine
8
Bortezomib
8
duvelisib
7
Vorinostat
7
Methotrexate
7
Magnetic Resonance Spectroscopy
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lymphoma, T-Cell
×
cobomarsen
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts
NCT03837457
2020-11-19
PRISM
miRagen Therapeutics, Inc.
Phase 2
Terminated
8 enrolled